Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Genetics Institute Inc.
Joseph Edelman of Prudential Securities upgraded the stock to "buy" from "hold" with a one-year price
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury